Tenofovir alafenamide in prevention of hepatitis B virus transmission in moth-ers with high viral load
Objective To investigate the efficacy and safety of Tenofovir alafenamide(TAF)and Tenofovir diso-proxil fumarate(TDF)therapy for blocking vertical transmission of HBV in mothers infected with chronic high viral load.Methods A total of 116 pregnant women with high viral load were prospectively selected,divided into TAF group(56 cases)and TDF group(60 cases),and the drug was started at 24-28 gestational weeks,and HBV DNA,HBsAg and HBeAg were detected at 24-28,32-36 gestational weeks and delivery in both groups.For neonates at birth and 7 months of age,HBV DNA,HBsAg,and HBeAg were detected.Results At delivery,for 92.9％in the TAF group and 95％in the TDF group,the serum HBV DNA decreased to less than 2.0 x 105 IU/ml.In the TAF group,there were 57 neonates(1 case had a twin),4 cases(7.01％)were HBsAg positive at birth,1 case was HBV DNA positive,accounting for 1.75％.For the 60 neonates in the TDF group,2 cases(3.33％)were HBsAg positive at birth,and HBV DNA was all negative.When the neonates grew to 7 months of age,both the two groups were negative for HBsAg and HBV DNA,and Anti-HBs all were positive,the bloc-king success rate was 100％.No obvious adverse reactions were found in the mothers in the two groups,and there were no obvious growth and development disorders at birth,28,48,96 weeks for the neonates.Conclusion TAF therapy was well tolerated for highly viraemic mothers and effectively blocked the transmission of HBV.There were no safety concerns during the postpartum follow-up.
万方数据
维普
